Completion of the Safety Lead-In and Opening of Ph 2 of the AIPAC-003 Ph 2/3 Trial in Metastatic Breast Cancer Announced November 7, 2023
First Patient Dosed in the Registrational Ph 3 Study of Olverembatinib in 1L Ph+ ALL Patients October 25, 2023
First Patients Dosed in First-in-Human Ph 1 Study of FX-909 in Advanced Solid Tumors, Including Urothelial Cancer October 25, 2023
Enrollment ex-China in Ph 3 REGAL Trial for Galinpepimut-S in AML Expected to be Completed in Nov 2023 October 18, 2023
Clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab and cetuximab to be discontinued October 18, 2023
Dose Escalation Completed in Ph 1 Trial of INB-100; Enrollment for the Ph 2 Trial of INB-400 in 1L GBM initiated October 18, 2023
US FDA places lacutamab IND on partial clinical hold for new patient enrollment following one unexpected severe adverse reaction October 11, 2023
EXKIVITY® (mobocertinib) to be voluntary withdrawn from the U.S. for adult patients with EGFR Exon20 insertion+ mNSCLC whose disease has progressed on or after platinum-based chemotherapy October 11, 2023
First Subjects dosed in Ph 2 Portion of Trial Evaluating Annamycin + Cytarabine (Ara-C) for the Treatment of AML October 11, 2023
First Patient dosed in Landmark STAR-LLD Lenalidomide Ph 1b Trial in Multiple Myeloma October 11, 2023
Enrollment of 120 Patients for Ph 3 Trial of Denifanstat + Bevacizumab for Treatment of Recurrent GBM completed October 3, 2023
Ph 3 ENHANCE-2 study of magrolimab in patients with AML with TP53 mutations discontinued October 3, 2023
Ph 1/2 Study of Azeliragon in Patients Refractory to 1L Treatment of Metastatic Pancreatic Cancer initiated October 3, 2023
Ph 2 Study of Masofaniten (EPI-7386) + Enzalutamide in Patients with Metastatic CRPC initiated September 26, 2023
First Patient Dosed in Ph 1/2a Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer September 26, 2023
First Patient dosed in Ph 1/2 Trial of IMPT-314 for the Treatment of Aggressive B-cell Lymphoma September 26, 2023
First Patient in Ph 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ September 26, 2023
Patient Dosing with MT-302 initiated in Ph 1 Study for Advanced or Metastatic Epithelial Tumors September 19, 2023
